News

Madrigal Pharmaceuticals Shares Rise After Receiving U.S. Patent for Rezdiffra Treatment
Madrigal Pharmaceuticals shares rose after the biopharmaceutical company received a U.S. patent for its Rezdiffra treatment. Shares were up 11% at $345.24 Wednesday. The stock has been up 12.8% this ...
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)
Provides Protection Through Sept. 2044; Will Be Listed in FDA’s Orange Book CONSHOHOCKEN, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical ...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...
Madrigal stock jumps as patent protection for MASH treatment extended
The extended patent protection strengthens Madrigal’s market position by preventing generic competition for over two decades, potentially securing long-term revenue streams for the biopharmaceutical ...
Zacks Investment Research on MSN1h
Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last?
Madrigal (MDGL) shares rallied 10.9% in the last trading session to close at $344.97. This move can be attributable to notable volume with a higher number of shares being traded than in a typical ...
InvestorsHub on MSN22h
Madrigal Pharmaceuticals shares surge after extended patent protection for MASH therapy
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) saw its stock climb 6.1% following the announcement that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its MASH treatment, ...
Healio4d
Resmetirom, glucagon receptor agonists appear similarly effective for MASLD, MASH
In patients with metabolic-associated steatotic liver disease or metabolic-associated steatohepatitis, resmetirom and ...